

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have also been amended to delete improper multiple dependencies and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By *Raymond C. Stewart* #36,623  
Raymond C. Stewart, #21,066

RCS/cgc  
0425-0832P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment: Version With Markings Showing Changes Made

(Rev. 01/22/01)

**VERSION WITH MARKINGS SHOWING CHANGES MADE**

The specification has been amended to provide cross-referencing to the International Application.

The claims have been amended as follows:

12. (Amended) The method for manufacturing as claimed in claim 6 [or 7], wherein the slightly soluble pharmaceutical agent is a cyclic GMP phosphodiesterase inhibitor.

RECEIVED - JUL 1 1994